Welcome to LookChem.com Sign In|Join Free

Cas Database

2936-08-5

2936-08-5

Identification

Synonyms:Valerylchloride, 2-propyl- (6CI,7CI,8CI);2,2-Di-n-propylacetyl chloride;2-Propylpentanoyl chloride;2-Propylvaleryl chloride;2-n-Propyl-n-valeroylchloride;4-(Chloroacetyl)heptane;Dipropylacetyl chloride;Valproic acidchloride;Valproyl chloride;

Post Buying Request Now
Entrust LookChem procurement to find high-quality suppliers faster

Safety information and MSDS view more

  • Pictogram(s):CorrosiveC

  • Hazard Codes:C,Xn

  • Signal Word:Danger

  • Hazard Statement:H314 Causes severe skin burns and eye damage

  • First-aid measures: General adviceConsult a physician. Show this safety data sheet to the doctor in attendance.If inhaled If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. In case of skin contact Wash off with soap and plenty of water. Consult a physician. In case of eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. If swallowed Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

  • Fire-fighting measures: Suitable extinguishing media Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. Wear self-contained breathing apparatus for firefighting if necessary.

  • Accidental release measures: Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust. For personal protection see section 8. Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment must be avoided. Pick up and arrange disposal. Sweep up and shovel. Keep in suitable, closed containers for disposal.

  • Handling and storage: Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Avoid exposure - obtain special instructions before use.Provide appropriate exhaust ventilation at places where dust is formed. For precautions see section 2.2. Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

  • Exposure controls/personal protection:Occupational Exposure limit valuesBiological limit values Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday. Eye/face protection Safety glasses with side-shields conforming to EN166. Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU). Skin protection Wear impervious clothing. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace. Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique(without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it. Respiratory protection Wear dust mask when handling large quantities. Thermal hazards

Supplier and reference price

  • Manufacture/Brand
  • Product Description
  • Packaging
  • Price
  • Delivery
  • Purchase
  • Manufacture/Brand:TCI Chemical
  • Product Description:2-Propylvaleryl Chloride >99.0%(GC)
  • Packaging:5mL
  • Price:$ 112
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:SynQuest Laboratories
  • Product Description:2-Propylpentanoyl chloride 98%
  • Packaging:5 g
  • Price:$ 65
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:SynQuest Laboratories
  • Product Description:2-Propylpentanoyl chloride 98%
  • Packaging:25 g
  • Price:$ 215
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:SynQuest Laboratories
  • Product Description:2-Propylpentanoyl chloride 98%
  • Packaging:1 g
  • Price:$ 25
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:American Custom Chemicals Corporation
  • Product Description:2,2-DI-N-PROPYLACETYL CHLORIDE 95.00%
  • Packaging:25G
  • Price:$ 1214.14
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:American Custom Chemicals Corporation
  • Product Description:2,2-DI-N-PROPYLACETYL CHLORIDE 95.00%
  • Packaging:5G
  • Price:$ 801.69
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:Alfa Aesar
  • Product Description:2,2-Di-n-propylacetyl chloride, 98%
  • Packaging:5g
  • Price:$ 57.4
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:AK Scientific
  • Product Description:2,2-Di-N-propylacetylchloride
  • Packaging:25g
  • Price:$ 231
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:AK Scientific
  • Product Description:2,2-Di-N-propylacetylchloride
  • Packaging:1g
  • Price:$ 71
  • Delivery:In stock
  • Buy Now

Relevant articles and documentsAll total 37 Articles be found

Incorporation of [3H]valproic acid into lipids in GT1-7 neurons

Siafaka-Kapadai, Athanassia,Patiris, Marinis,Bowden, Charles,Javors, Martin

, p. 207 - 212 (1998)

Valproic acid (2-propylpentanoic acid, valproate, VPA), an 8-carbon, branched chain fatty acid, is effectively used in the treatment of mania and epilepsy. The biochemical mechanisms by which this drug has its therapeutic effects are not yet established. The purpose of this study was to partially characterize the incorporation of [3H]VPA into phospholipids of GT1-7 neurons, an immortalized hypothalamic cell line. GT1-7 neurons were grown to confluence in culture dishes, and then were incubated with various concentrations of [3H]VPA between 10 and 400 μg/mL for various times up to 20 hr. Total lipids were extracted and phospholipids were separated from neutral lipids using TLC. Our results indicate that [3H]VPA (10 μg/mL) was incorporated into phospholipids of GT1-7 neurons in a time-dependent and saturable manner over 300 min. Subsequent separation of the lipid fraction by TLC indicated that 44.4% of the radioactivity taken up by the cells was incorporated into phospholipids and neutral lipids. One of the phospholipids migrated with a slightly lower R(f) value than authentic phosphatidylcholine. Our results show that the incorporation of VPA into phospholipids and glycerides was linear with VPA concentrations from 10 to 400 μg/mL. Finally, we synthesized 1-acyl-2-valproyl-sn-glycero-3-phosphocholine and validated its structure with nuclear magnetic resonance and electrospray mass spectrometry to verify the structure of this compound, confirming that this compound is structurally possible. We conclude that VPA is incorporated into lipids in GT1-7 neurons and discuss the possible effects of valproyl phospholipids on neuronal functional properties. Copyright (C) 1998 Elsevier Science, Inc.

Synthesis and pharmacological activity of two derivatives of the amide of valproic acid

Bechar, Elly,Astroug, Henri

, p. 273 - 276 (1997)

Valproic acid (VPA), a synthetic branched-chain fatty acid, and its pro-drug the primary amide (VPD) are effective and widely used anti-epileptic agents. Although the use of VPA has grown in recent years, major side effects are still associated with this drug. We presume that it is possible, without loosing the VPD pharmacological profile, to obtain new compounds by undertaking substitutions in the CONH group. N,N'-bis-(2-propylpentanoyl)-1,2-ethane-diamine (3) and N,N'-bis-(2-propylpentanoyl)-1,3-propane-diamine (4) were obtained from VPA (1) using a method reported in the literature. The chemical structures of the new compounds were demonstrated by elemental analysis, IR, and 1H NMR spectroscopy. Both compounds are less toxic and more effective in protecting the animals from death caused by PTZ than VPD after intraperitoneal administration to mice.

Novel phosphinic and phosphonic acid analogues of the anticonvulsant valproic acid

Kehler, Jan,Hansen, Henrik I.,Sanchez, Connie

, p. 2547 - 2548 (2000)

1-Propylbutylphosphinic acid 2, (1-propylbutyl)methylphosphinic acid 3 and 1-propylbutylphosphonic acid 4 have been synthesized as bioisosteres of the corresponding carboxylic acid valproate 1, which is a potent anticonvulsant. The novel phosphinic and phosphonic acids were tested for their anticonvulsant activity and were found to be inactive. (C) 2000 Elsevier Science Ltd.

Novel valproic aminophenol amides with enhanced glial cell viability effect

Alpuche-García, Andrea,Dávila-González, Xochitl,Arregui, Leticia,Beltrán, Hiram I.

, p. 12391 - 12399 (2017)

New valproic acid derivatives were synthesized by coupling valproyl chloride with ortho-aminophenols, resulting in seven N-(ortho-hydroxyphenyl)valproamides. These amides share similar structural characteristics and exhibit tuneable electronic and steric contributions either without particular substituents, or through the inclusion of electro-donating (-Me), electro-withdrawing (-NO2) or pi electro-donating/sigma electro-withdrawing (-Cl) substituents at the aromatic ring. The identity of such derivatives was evidenced through spectroscopic characterization using FTIR, 1H, 13C and HETCOR NMR, as well as by analyzing their melting points. In particular, for three derivatives it was feasible to determine their chemical structures in the crystal phase; all three behaved in a similar fashion and exhibited very similar conformations independent of the attached substituents. The base compound was found to exhibit 15.8 times more activity in C6 cells and 4.4 times more activity in U373 cells compared with VPA. In general, the parent compound, or those having-Me as a substituent, presented a greater effect on C6 cells than U373 cells. However, those with-NO2 and-Cl substituents, as well as VPA, required similar doses for the IC50 in both cell lines. Modification of the base compound with a-Me or-NO2 substituent increased the effect on cell viability to ca. 20 times that of VPA in both C6 and U373, indicating that a larger structure causes an important enhancement in the inhibition of cell viability. In both cell lines,-Cl containing derivatives were the most active compounds. For these derivatives, an activity increase of ca. 59 and 47 times that of VPA was observed for C6 and U373 cells, respectively. An important perspective is that VPA analogues possessing an aromatic ring with a-Cl substituent may become central structures in the search for more potent pharmaceutical prototypes.

Practical aspects of cyclic voltammetry: How to estimate reduction potentials when irreversibility prevails

Espinoza, Eli M.,Clark, John A.,Soliman, Joey,Derr, James B.,Morales, Maryann,Vullev, Valentine I.

, p. H3175 - H3187 (2019)

What is the best approach for estimating standard electrochemical potentials, E(0), from voltammograms that exhibit chemical irreversibility? The lifetimes of the oxidized or reduced forms of the majority of known redox species are considerably shorter than the voltammetry acquisition times, resulting in irreversibility and making the answer to this question of outmost importance. Halfwave potentials, E(1/2), provide the best experimentally obtainable representation of E(0). Due to irreversible oxidation or reduction, however, the lack of cathodic or anodic peaks in cyclic voltammograms renders E(1/2) unattainable. Therefore, we evaluate how closely alternative potentials, readily obtainable from irreversible voltammograms, estimate E(0). Our analysis reveals that, when E(1/2) is not available, inflection-point potentials provide the best characterization of redox couples. While peak potentials are the most extensively used descriptor for irreversible systems, they deviate significantly from E(0), especially at high scan rates. Even for partially irreversible systems, when the cathodic peak is not as pronounced as the anodic one, the half-wave potentials still provide the best estimates for E(0). The importance of these findings extends beyond the realm of electrochemistry and impacts fields, such as materials engineering, photonics, cell biology, solar energy engineering and neuroscience, where cyclic voltammetry is a key tool.

N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells

Prestegui-Martel, Berenice,Bermúdez-Lugo, Jorge Antonio,Chávez-Blanco, Alma,Due?as-González, Alfonso,García-Sánchez, José Rubén,Pérez-González, Oscar Alberto,Padilla-Martínez, Itzia Irene,Fragoso-Vázquez, Manuel Jonathan,Mendieta-Wejebe, Jessica Elena,Correa-Basurto, Ana María,Méndez-Luna, David,Trujillo-Ferrara, José,Correa-Basurto, José

, p. 140 - 149 (2016)

Epigenetic alterations are associated with cancer and their targeting is a promising approach for treatment of this disease. Among current epigenetic drugs, histone deacetylase (HDAC) inhibitors induce changes in gene expression that can lead to cell death in tumors. Valproic acid (VPA) is a HDAC inhibitor that has antitumor activity at mM range. However, it is known that VPA is a hepatotoxic drug. Therefore, the aim of this study was to design a set of VPA derivatives adding the arylamine core of the suberoylanilide hydroxamic acid (SAHA) with different substituents at its carboxyl group. These derivatives were submitted to docking simulations to select the most promising compound. The compound 2 (N-(2-hydroxyphenyl)-2-propylpentanamide) was the best candidate to be synthesized and evaluated in vitro as an anti-cancer agent against HeLa, rhabdomyosarcoma and breast cancer cell lines. Compound 2 showed a better IC50 (μM range) than VPA (mM range) on these cancer cells. And also, 2 was particularly effective on triple negative breast cancer cells. In conclusion, 2 is an example of drugs designed in silico that show biological properties against human cancer difficult to treat as triple negative breast cancer.

Molecular modeling and LC–MS-based metabolomics of a glutamine-valproic acid (Gln-VPA) derivative on HeLa cells

Fragoso-Vázquez,Méndez-Luna,Rosales-Hernández,Luna-Palencia,Estrada-Pérez,Fromager, Benedicte,Vásquez-Moctezuma,Correa-Basurto

, p. 1077 - 1089 (2021)

Abstract: Glutaminase plays an important role in carcinogenesis and cancer cell growth. This biological target is interesting against cancer cells. Therefore, in this work, in silico [docking and molecular dynamics (MD) simulations] and in vitro methods (antiproliferative and LC–MS metabolomics) were employed to assay a hybrid compound derived from glutamine and valproic acid (Gln-VPA), which was compared with 6-diazo-5-oxo-l-norleucine (DON, a glutaminase inhibitor) and VPA (contained in Gln-VPA structure). Docking results from some snapshots retrieved from MD simulations show that glutaminase recognized Gln-VPA and DON. Additionally, Gln-VPA showed antiproliferative effects in HeLa cells and inhibited glutaminase activity. Finally, the LC–MS-based metabolomics studies on HeLa cells treated with either Gln-VPA (IC60 = 8?mM) or DON (IC50 = 3.5?mM) show different metabolomics behaviors, suggesting that they modulate different biological targets of the cell death mechanism. In conclusion, Gln-VPA is capable of interfering with more than one pharmacological target of cancer, making it an interesting drug that can be used to avoid multitherapy of classic anticancer drugs. Graphic abstract: [Figure not available: see fulltext.].

PROCESS FOR THE PREPARATION OF EFLORNITHINE DERIVATIVES AND THEIR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF

-

Paragraph 0054-0056, (2021/12/28)

This invention relates to a process of large scale manufacturing of 2-Amino-2-(difluoromethyl)-5-(2-propylpentanamido) pentanoic acid derivatives and their pharmaceutically acceptable salts, polymorphs, stereoisomers, enantiomers thereof, by two step process. It further discloses the use of 2-Amino-2-(difluoromethyl)-5-(2-propylpentanamido) pentanoic acid derivatives and their pharmaceutically acceptable forms thereof for the treatment of cancer, trypanosomiasis and excessive hair growth.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

-

Paragraph 00135-00136, (2020/02/23)

The compositions and compounds of formula I and formula II which includes nucleic acid synthesis inhibitor conjugates or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These conjugates may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of cancer or its associated complications.

Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class i HDAC Enzymes and Cancer Cell Proliferation

Tng, Jiahui,Lim, Junxian,Wu, Kai-Chen,Lucke, Andrew J.,Xu, Weijun,Reid, Robert C.,Fairlie, David P.

supporting information, p. 5956 - 5971 (2020/06/05)

AR-42 is an orally active inhibitor of histone deacetylases (HDACs) in clinical trials for multiple myeloma, leukemia, and lymphoma. It has few hydrogen bond donors and acceptors but is a chiral 2-arylbutyrate and potentially prone to racemization. We report achiral AR-42 analogues incorporating a cycloalkyl group linked via a quaternary carbon atom, with up to 40-fold increased potency against human class I HDACs (e.g., JT86, IC50 0.7 nM, HDAC1), 25-fold increased cytotoxicity against five human cancer cell lines, and up to 70-fold less toxicity in normal human cells. JT86 was ninefold more potent than racAR-42 in promoting accumulation of acetylated histone H4 in MM96L melanoma cells. Molecular modeling and structure-activity relationships support binding to HDAC1 with tetrahydropyran acting as a hydrophobic shield from water at the enzyme surface. Such potent inhibitors of class I HDACs may show benefits in diseases (cancers, parasitic infections, inflammatory conditions) where AR-42 is active.

Anti-epileptic activity, toxicity and teratogenicity in CD1 mice of a novel valproic acid arylamide derivative, N-(2-hydroxyphenyl)-2-propylpentanamide

Chamorro-Cevallos, Germán,Correa-Basurto, José,Cristóbal-Luna, José Melesio,Mendoza-Figueroa, Humberto L.

, (2020/05/25)

N-(2-hydroxyphenyl)-2-propylpentamide (HO-AAVPA) is a novel arylamide derivative of valproic acid (VPA) designed in silico, with better antioxidant and antiproliferative effect on cancer cell lines than VPA. This study was aimed to evaluate the anticonvulsant activity, the toxicity and teratogenicity produced in HO-AAVPA-treated CD1 mice using VPA as positive control. With the maximal electroshock (MES)- and pentylenetetrazole (PTZ)-induced seizure models, HO-AAVPA reduced the time of hind limb extension, stupor and recovery, the number of clonic and tonic seizures and the mortality rate in a dose-dependent manner, obtaining an ED50 of 370 and 348 mg/kg for MES and PTZ, respectively. On the rotarod test, mice administered with 600 mg/kg HO-AAVPA manifested reduced locomotor activity (2.78%); while HO-AAVPA at 300 mg/kg and VPA at 500 mg/kg gave a similar outcome (~60%). The LD50 of 936.80 mg/kg herein found for HO-AAVPA reflects moderate toxicity. Concerning teratogenicity, the administration of HO-AAVPA to pregnant females at 300 and 600 mg/kg on gestation day (GD) 8.5 generated less visceral and skeletal alterations in the fetuses, as well as, minor rate of modifications in the expression pattern of the neuronal marker Tuj1 and endothelial marker PECAM1 in embryos, that those induced by VPA administration. Altered embryonic development occurred with less frequency and severity with HO-AAVPA at 600 mg/kg than VPA at 500 mg/kg. In conclusion, the protective effect against convulsions provided by HO-AAVPA was comparable to that of VPA in the MES and PZT seizure models, showed lower toxicity and less damage to embryonic and fetal development.

Process route upstream and downstream products

Process route

valproic acid
99-66-1

valproic acid

valproyl chloride
2936-08-5

valproyl chloride

Conditions
Conditions Yield
With thionyl chloride; In toluene; Heating;
100%
With thionyl chloride; at 10 - 20 ℃; for 4h;
94%
With thionyl chloride; In N,N-dimethyl-formamide; Reflux;
93.6%
With thionyl chloride; at 10 - 80 ℃;
90%
With thionyl chloride; In N,N-dimethyl-formamide; at -5 ℃; for 2h; Reflux;
90%
With thionyl chloride;
With thionyl chloride;
With oxalyl dichloride;
With thionyl chloride; Heating;
With oxalyl dichloride; In N,N-dimethyl-formamide; benzene; for 2h; Ambient temperature;
With thionyl chloride; In benzene;
With thionyl chloride;
With thionyl chloride; for 2h; Heating;
With thionyl chloride; Heating;
With thionyl chloride; for 1h; Heating;
With oxalyl dichloride; N,N-dimethyl-formamide; In dichloromethane; for 1h;
With thionyl chloride; In dichloromethane; at 25 ℃; for 10h;
With thionyl chloride; calcium chloride; In sodium hydroxide; at 20 ℃;
With oxalyl dichloride; N,N-dimethyl-formamide; In dichloromethane; for 1h;
With thionyl chloride;
With thionyl chloride; at 20 ℃;
With oxalyl dichloride; N,N-dimethyl-formamide; for 4h;
With thionyl chloride; In dichloromethane; Cooling with ice; Reflux;
With thionyl chloride;
With oxalyl dichloride; In dichloromethane; N,N-dimethyl-formamide; for 2h; Reflux;
With oxalyl dichloride; In dichloromethane; N,N-dimethyl-formamide; at 0 - 20 ℃; for 2.33333h; Inert atmosphere;
With oxalyl dichloride; In dichloromethane; N,N-dimethyl-formamide; at 0 - 20 ℃; for 2h; Inert atmosphere;
With oxalyl dichloride; at 0 ℃; for 8h;
With thionyl chloride; at 86 ℃; for 2h; Reagent/catalyst; Temperature;
With thionyl chloride; In acetonitrile; at 20 ℃; for 24h;
With oxalyl dichloride; In dichloromethane; for 12h; Cooling with ice;
With oxalyl dichloride; Cooling with acetone-dry ice;
With oxalyl dichloride; N,N-dimethyl-formamide; In dichloromethane; at 0 - 20 ℃; for 4h;
With chlorinating agent; In dichloromethane; at 0 ℃;
With thionyl chloride; for 2h;
With oxalyl dichloride; at 20 ℃; for 4h;
With thionyl chloride; In dichloromethane; at 25 - 45 ℃;
thionyl chloride
7719-09-7

thionyl chloride

valproic acid
99-66-1

valproic acid

valproyl chloride
2936-08-5

valproyl chloride

Conditions
Conditions Yield
In dichloromethane; at 25 ℃; for 12h;
ethyl 2-propylpentanoate
17022-31-0

ethyl 2-propylpentanoate

valproyl chloride
2936-08-5

valproyl chloride

Conditions
Conditions Yield
Multi-step reaction with 2 steps
1: sodium hydroxide / methanol; water / 3 h / Reflux
2: chlorinating agent / dichloromethane / 0 °C
With sodium hydroxide; In methanol; dichloromethane; water;
valproyl chloride
2936-08-5

valproyl chloride

Conditions
Conditions Yield
valproyl chloride
2936-08-5

valproyl chloride

valpromide
2430-27-5

valpromide

Conditions
Conditions Yield
With ammonia; In methanol;
With ammonium hydroxide; In acetonitrile; at 0 ℃; for 0.166667h;
With ammonium hydroxide; In water; acetonitrile; at 0 ℃; for 2h;
valproyl chloride
2936-08-5

valproyl chloride

4-amino-3-chlorobenzenesulfonamide
53297-68-0

4-amino-3-chlorobenzenesulfonamide

2-propyl-pentanoic acid (2-chloro-4-sulfamoyl-phenyl)-amide

2-propyl-pentanoic acid (2-chloro-4-sulfamoyl-phenyl)-amide

Conditions
Conditions Yield
With triethylamine; In acetonitrile; at 20 ℃;
valproyl chloride
2936-08-5

valproyl chloride

4-amino-o-xylene
95-64-7

4-amino-o-xylene

2-Propyl-valeriansaeure-<3,4-dimethyl-anilid>
4344-69-8

2-Propyl-valeriansaeure-<3,4-dimethyl-anilid>

Conditions
Conditions Yield
In benzene;
valproyl chloride
2936-08-5

valproyl chloride

(E)-5-((tert-butyldiphenylsilyloxy)methyl)-5-(hydroxymethyl)-3-((1-methyl-1H-indol-4-yl)methylene)dihydrofuran-2(3H)-one
1610776-23-2

(E)-5-((tert-butyldiphenylsilyloxy)methyl)-5-(hydroxymethyl)-3-((1-methyl-1H-indol-4-yl)methylene)dihydrofuran-2(3H)-one

(E)-(2-((tert-butyldiphenylsilyloxy)methyl)-4-((1-methyl-1H-indol-4-yl)methylene)-5-oxotetrahydrofuran-2-yl)methyl 2-propylpentanoate
1610776-29-8

(E)-(2-((tert-butyldiphenylsilyloxy)methyl)-4-((1-methyl-1H-indol-4-yl)methylene)-5-oxotetrahydrofuran-2-yl)methyl 2-propylpentanoate

Conditions
Conditions Yield
With dmap; triethylamine; In dichloromethane; at 20 ℃;
92%
valproyl chloride
2936-08-5

valproyl chloride

(E)-5-((tert-butyldiphenylsilyloxy)methyl)-5-(hydroxymethyl)-3-((1-methyl-1H-indol-6-yl)methylene)dihydrofuran-2(3H)-one
1610776-25-4

(E)-5-((tert-butyldiphenylsilyloxy)methyl)-5-(hydroxymethyl)-3-((1-methyl-1H-indol-6-yl)methylene)dihydrofuran-2(3H)-one

(E)-(2-((tert-butyldiphenylsilyloxy)methyl)-4-((1-methyl-1H-indol-6-yl)methylene)-5-oxotetrahydrofuran-2-yl)methyl 2-propylpentanoate
1610776-31-2

(E)-(2-((tert-butyldiphenylsilyloxy)methyl)-4-((1-methyl-1H-indol-6-yl)methylene)-5-oxotetrahydrofuran-2-yl)methyl 2-propylpentanoate

Conditions
Conditions Yield
With dmap; triethylamine; In dichloromethane; at 20 ℃;
96%
valproyl chloride
2936-08-5

valproyl chloride

(E)-5-((tert-butyldiphenylsilyloxy)methyl)-5-(hydroxymethyl)-3-((1-methyl-1H-indol-7-yl)methylene)dihydrofuran-2(3H)-one
1610776-28-7

(E)-5-((tert-butyldiphenylsilyloxy)methyl)-5-(hydroxymethyl)-3-((1-methyl-1H-indol-7-yl)methylene)dihydrofuran-2(3H)-one

(E)-(2-((tert-butyldiphenylsilyloxy)methyl)-4-((1-methyl-1H-indol-7-yl)methylene)-5-oxotetrahydrofuran-2-yl)methyl 2-propylpentanoate
1610776-32-3

(E)-(2-((tert-butyldiphenylsilyloxy)methyl)-4-((1-methyl-1H-indol-7-yl)methylene)-5-oxotetrahydrofuran-2-yl)methyl 2-propylpentanoate

Conditions
Conditions Yield
With dmap; triethylamine; In dichloromethane; at 20 ℃;
86%

Global suppliers and manufacturers

Global( 13) Suppliers
  • Company Name
  • Business Type
  • Contact Tel
  • Emails
  • Main Products
  • Country
  • Kono Chem Co.,Ltd
  • Business Type:Other
  • Contact Tel:86-29-86107037-8015
  • Emails:info@konochemical.com
  • Main Products:82
  • Country:China (Mainland)
  • Finetech Industry Limited
  • Business Type:Trading Company
  • Contact Tel:86-27-87465837
  • Emails:sales@finetechnology-ind.com
  • Main Products:29
  • Country:China (Mainland)
  • Antimex Chemical Limied
  • Business Type:Lab/Research institutions
  • Contact Tel:0086-21-50563169
  • Emails:anthony@antimex.com
  • Main Products:163
  • Country:China (Mainland)
  • Chemlyte Solutions
  • Business Type:Other
  • Contact Tel:+86-189 8945 5137
  • Emails:sales@chemlytesolutions.com
  • Main Products:200
  • Country:China (Mainland)
  • Yinghao Pharm Co.,Ltd.
  • Business Type:Lab/Research institutions
  • Contact Tel:+86-519-85390519
  • Emails:sales@haopharm.com
  • Main Products:1
  • Country:China (Mainland)
close
Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 2936-08-5
Post Buying Request Now
close
Remarks: The blank with*must be completed